

## Diagnostic value of BAL fluid cellular profile and enzymes in infectious pulmonary disorders

N.A.M. Cobben\*, J.A. Jacobs\*\*, M.P. van Dieijen-Visser\*\*\*, P.G.H. Mulder<sup>†</sup>,  
E.F.M. Wouters\*, M. Drent\*

*Diagnostic value of BAL fluid cellular profile and enzymes in infectious pulmonary disorders. N.A.M. Cobben, J.A. Jacobs, M.P. van Dieijen-Visser, P.G.H. Mulder, E.F.M. Wouters, M. Drent. ©ERS Journals Ltd 1999.*

**ABSTRACT:** Determination of the cellular profile of bronchoalveolar lavage fluid (BALF), lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) appeared to be useful in monitoring pulmonary damage. The aim of this study was to investigate whether the cellular profile, LDH, its isoenzyme pattern and/or ALP in BALF are useful in the diagnostic work-up of patients with suspected pneumonia.

The BALF specimens of 80 patients were studied. Group I consisted of patients with a pulmonary infection (n=33) and group II of patients without signs of a pulmonary infection (n=47). Differentiation between these two groups was based upon the results of microscopy and quantitative cultures.

The absolute as well as relative numbers of polymorphonuclear neutrophils (PMNs) was significantly higher in group I compared to group II (p<0.0001). The absolute number of PMNs showed a sensitivity of predicting the correct group of 95.7% and a specificity of 84.8%. The LDH activity in BALF was significantly higher in group I than in group II (p<0.0001). The LDH<sub>4</sub>/LDH<sub>5</sub> ratio in BALF was lower in group I compared to group II (p<0.0001) and appeared to be the best discriminator between the two groups with a sensitivity of 93.6% and a specificity of 93.9%.

In conclusion, the number of polymorphonuclear neutrophils as well as the lactate dehydrogenase activity, particularly its isoenzymes, in bronchoalveolar lavage fluid appeared to be of potential practical value to distinguish between infectious and noninfectious pulmonary disorders.

*Eur Respir J 1999; 14: 496–502.*

\*Dept of Pulmonology, \*\*Dept of Medical Microbiology, \*\*\*Dept of Clinical Chemistry, University Hospital Maastricht, <sup>†</sup>Dept of Epidemiology and Biostatistics, Erasmus University, Rotterdam, the Netherlands.

Correspondence: M. Drent  
University Hospital of Maastricht  
Dept of Pulmonology  
PO BOX 5800  
6202 AZ Maastricht  
The Netherlands  
Fax: 31 433875051

Keywords: Bronchoalveolar lavage  
cellular profile  
lactate dehydrogenase  
neutrophils  
pneumonia

Received: December 9 1998  
Accepted after revision July 13 1999

Bronchoalveolar lavage (BAL) is broadly indicated in every patient with unclear abnormalities demonstrated on chest radiographs of unknown aetiology. The underlying disorders may be of infectious, noninfectious, immunologic or of malignant aetiology [1]. Hospital acquired pneumonia, including ventilator associated pneumonia, represents a major source of morbidity and mortality in hospital patients [2, 3]. Usually, a pulmonary infection is diagnosed using a number of easily available parameters such as temperature changes, the number of serum leukocytes and bacteria present in the Gram stain, as well as new or worsening infiltrates upon chest radiography. Each variable may have a reasonable sensitivity for pneumonia. However, the specificity is rather poor as fever, serum leukocytosis, and/or radiological abnormalities in hospital patients are often due to noninfectious causes [4]. Presently, cultures of BAL fluid (BALF) are a generally accepted tool in diagnosing pneumonia. A cutoff of quantitative cultures from BALF of  $\geq 10^4$  colony forming units (cfu)·mL<sup>-1</sup> is recommended and appropriate [5]. The sensitivity of BAL (histological diagnosis as gold standard) in the diagnosis of bacterial infections ranges 60–90%; in mycobacterial, fungal, and most viral infections 70–80% and in *Pneumocystis carinii* pneumonia 90–95% [1, 5]. However, it takes 2–4 days before quantitative

cultures of any technique, either invasive or noninvasive, are available. The use of specific markers, such as the presence of intracellular microorganisms [6], the levels of circulating serum cytokines [7], the levels of endotoxins and the detection of elastin fibres [4] can provide a rapid diagnosis of pneumonia. Most of these tests are not available in every hospital laboratory, and therefore, of less clinical relevance in the management of patients with suspected pneumonia with respect to the decision to initiate antibiotic treatment.

Parameters most often used to detect pulmonary inflammation in BALF are quantitative measures of the degree of the inflammatory response. Cellular changes observed in BALF during inflammation include an activation of alveolar macrophages (AMs) and an influx of polymorphonuclear neutrophils (PMNs). Biochemical changes in BALF are suggested to be useful to detect pulmonary injury [8]. An increase of the activity of lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) or of other enzymes which are normally intracellular in the recovered BALF, reflects lung parenchyma cell damage or cell death. The ALP activity in BALF has been associated with type II cell damage or stimulation [9]. These latter cells are normally not present in BALF. Several pulmonary disorders have been associated with elevated LDH

activity in serum as well as in BALF [10]. Lung parenchymal cells and/or local inflammatory cells, including AMs and PMNs, may be potential sources of LDH in BALF.

It has been previously demonstrated that the LDH isoenzyme pattern differed between BALF samples with mainly PMNs (high LDH<sub>5</sub>) and BALF samples with mainly AMs (high LDH<sub>3</sub>) [11]. As a consequence, the LDH<sub>3</sub>/LDH<sub>5</sub> ratio appeared to be significantly lower in BALF samples with predominantly PMNs compared to BALF samples with mainly AMs.

The aim of the present study was to evaluate whether the cellular profile and/or enzyme activity, e.g. ALP, LDH and its isoenzymes in BALF, have additional practical value in the diagnostic work-up of patients with suspected pneumonia to distinguish between samples of an infectious and noninfectious aetiology.

## Methods

### General experimental design

The study was conducted at the University Hospital Maastricht, the Netherlands, from February 1996 to January 1998. Eighty BALF samples from hospitalized patients were used for this study. The indication for the lavage varied. Mostly, a pulmonary infection or a diffuse interstitial lung disease was suspected. Exclusion criteria were BALF recovery <35 mL and contamination with red blood cells and/or oropharyngeal cells. Additionally, these 80 BALF samples were divided into two groups: group I consisted of BALF samples obtained from patients with a confirmed pulmonary infection (n=33) (based on culture results  $\geq 10^4$  cfu·mL<sup>-1</sup>) and group II consisted of BALF samples from patients without signs of pulmonary infection (n=47) (based on negative culture results <10<sup>3</sup> cfu·mL<sup>-1</sup> and the absence of intracellular bacteria). The positive culture results of the BALF samples obtained from group I were: *Haemophilus influenzae* (n=7), *Staphylococcus aureus* (n=6), *Pseudomonas aeruginosa* (n=6), *Escherichia coli* (n=2), *Proteus mirabilis* (n=2), *Streptococcus pneumoniae* (n=1), *Klebsiella pneumoniae* (n=1), *K. oxytoca* (n=1), *Citrobacter diversus* (n=1), *P. aeruginosa* and *P. mirabilis* (n=1), *S. aureus* and *H. influenzae* (n=1), *S. pneumoniae* and *Neisseria meningitidis* (n=1), *E. coli* and *K. oxytoca* (n=1), *E. coli* and *H. influenzae* (n=1), *P. mirabilis* and *H. influenzae* (n=1). The patients of group II suffered from: drug-induced interstitial lung disease and pulmonary fibrosis (n=16), acute respiratory distress syndrome (ARDS) developed for several reasons (n=4), pulmonary manifestation of malignancy (n=3), sarcoidosis (n=2), cardiac failure and pulmonary oedema (n=2), lung contusion after trauma (n=3), immunocompromised disorders with chest radiograph abnormalities (n=5), chemical pneumonitis after aspiration (n=2) and no diagnosis (n=10). The majority of cases from the infectious group (n=25) were intubated and mechanically ventilated patients from the intensive care unit (ICU). In the group of noninfectious disorders, 26 of the cases were patients from the hospital ward and the other 25 cases were intubated and mechanically ventilated patients from the ICU. A group of eight healthy volunteers without a relevant medical history, was used as a control group.

### Bronchoalveolar lavage

BAL was performed as reported previously during fibreoptic bronchoscopy [12]. The procedure is briefly described. If the patient was intubated, the bronchoscope was introduced through the tube. Otherwise, BAL was performed by standardized washing of the involved lobe with four aliquots of 50 mL sterile saline (0.9% NaCl) at 37°C after premedication (0.5 mg atropine intramuscular and occasionally 5–10 mg diazepam orally), and local anaesthesia of the larynx and bronchial tree (lidocaine 0.5%). Upon arrival in the laboratory, the recovered volume of the BALF was recorded. The first fraction (bronchial fraction) was discarded and the remaining fractions were pooled. After mixing, the BALF was split into two portions, portion one was immediately sent to the department of clinical chemistry and portion two was used for cytological and microbiological analysis. The total cell count was performed in a Fuchs-Rosenthal haemocytometer chamber (Optik Labor Emergo, Landsmeer, the Netherlands).

Cyocentrifugation was performed with the Shandon Cytospin 3 apparatus (Shandon Scientific Ltd., Astmoor, UK) (31,000 ×g, 10 min, at room temperature low acceleration rate). In order to obtain monolayer preparations, the number of drops per preparation was adjusted according to the total cell count. The preparations were air dried and subsequently stained according to the May-Grünwald Giemsa (MGG) and Gram's staining methods. The differential cell count of the MGG-stained preparations was performed by one observer counting 500 nucleated cells. The number of cells containing intracellular organisms was expressed as a percentage of all nucleated cells counted [13]. In this study, BALF samples containing excessive amounts of red blood cells, squamous epithelial and/or ciliated cells, background debris or damaged nucleated cells were excluded from analysis. In addition, BALF samples demonstrating *P. carinii* cysts were excluded. Quantitative bacterial cultures were performed on appropriate media incubated both aerobically and anaerobically. Mycobacterial and fungal cultures were performed on all BALF samples. Cultures for viruses and *Legionella* spp. were performed, when clinically indicated. For infectious aetiology, BALF samples were defined as those samples with a quantitative culture yielding  $\geq 10^4$  cfu·mL<sup>-1</sup>. Regarding noninfectious aetiology, BALF samples were categorized if standard bacterial cultures yielded micro-organisms in quantities <10<sup>4</sup> cfu·mL<sup>-1</sup> and if other cultures failed to reveal any pathogen and the absence of intracellular organisms at microscopic examination.

### Laboratory tests

In the second portion of the BALF samples, chemical analyses including LDH, LDH isoenzymes, ALP, total protein and albumin were also performed.

The LDH activity was measured at 37°C by an enzymatic rate method, using pyruvate as a substrate. The test was performed on a Beckman Synchron CX-7 analyser (Beckman Instruments Inc, Mijdrecht, the Netherlands) with Beckman reagents (testkit 442660) and was optimized according to the recommendations of the Deutsche Gesellschaft für Klinische Chemie (DGKC-recommendations)

Table 1. – Summary of characteristics and serum laboratory results of the two groups studied and a healthy control group

	Group I (n=33)	Group II (n=47)	Control group (n=8)
M/F n	24/9	23/24	4/4
Age yrs	60±3	54±2	56±6
LDH U·L <sup>-1</sup>	727±50 <sup>#</sup>	1026±262 <sup>#</sup>	361±8
ALP U·L <sup>-1</sup>	180±47 <sup>#</sup>	160±26 <sup>#</sup>	78±3
Total protein g·L <sup>-1</sup>	50±2.0* <sup>#</sup>	58±2.2 <sup>#</sup>	72±0.5
Albumin g·L <sup>-1</sup>	18±1.2* <sup>#</sup>	25±1.7 <sup>#</sup>	43±0.3

Group I: patients with bacterial pulmonary infection; Group II: patients without a pulmonary infection. Data are expressed as mean±SEM. M: male; F: female; LDH: lactate dehydrogenase; ALP: alkaline phosphatase. \*: p<0.02 group I versus group II; #: p<0.001 versus control group.

[14]. The system monitors the reduction of pyruvate to L-lactate with the concurrent oxidation of β-nicotinamide adenine dinucleotide (NADH; reduced form) at 340 nm. The change in absorbance at 340 nm, caused by the disappearance of NADH was measured over a fixed time interval and is directly proportional to the LDH activity. The LDH activity was expressed in micromoles of substrate (pyruvate) converted per minute (U), per litre of serum, at 37°C. The measuring range is 10–1,800 U·L<sup>-1</sup>, for concentrations of 1,800–3,800 U·L<sup>-1</sup> the samples were automatically diluted with saline and reanalysed, while manual dilution was performed for higher concentrations. The reference ranges in serum for LDH are 200–450 U·L<sup>-1</sup>.

The surface charge difference was the basis on which the five LDH isoenzymes were separated by electrophoresis on the Beckman Appraise system (Beckman Instruments Inc) using the LDH isoenzyme electrophoresis test kit (655940) [14]. After separation of the LDH isoenzymes by electrophoresis, the agarose gel was incubated with a reaction mixture containing the LDH substrate lactate, the coenzyme NAD<sup>+</sup> and a tetrazolium salt. During this incubation, NADH formed at zones on the gel where the LDH isoenzymes were present. The NADH generated, was detected by its reduction of the tetrazolium salt to form coloured bands, which could be quantitated by scanning the gel at 600 nm.

Table 2. – Cellular characteristics in bronchoalveolar lavage fluid (BALF) samples of group I (infectious aetiology), group II (noninfectious aetiology) patients and of control subjects

	Group I (n=33)	Group II (n=47)	Control group (n=8)
Recovery mL	57.7±5.0 <sup>#</sup>	89.2±5.3***	95.7±12.8
Total cell count × 10 <sup>4</sup> cells·mL <sup>-1</sup>	329.1±84.8####	25.6±3.3***	14.3±1.3
PMNs × 10 <sup>4</sup> cells·mL <sup>-1</sup>	309.6±81.3####	5.5±1.2*** <sup>#</sup>	0.2±0.1
PMNs %	90.5±1.5####	21.6±3.4*** <sup>#</sup>	1.7±0.5
AMs × 10 <sup>4</sup> cells·mL <sup>-1</sup>	14.3±3.3	12.3±2.2	12.7±1.2
AMs %	7.0±1.3####	47.4±3.7*** <sup>###</sup>	89.1±1.7
Lymphocytes × 10 <sup>4</sup> cells·mL <sup>-1</sup>	4.5±1.5	7.1±1.4* <sup>###</sup>	1.0±0.3
Lymphocytes %	1.9±0.5 <sup>#</sup>	27.5±3.4*** <sup>###</sup>	6.8±2.1
Eosinophils × 10 <sup>4</sup> cells·mL <sup>-1</sup>	0.091±0.059	0.219±0.057*** <sup>#</sup>	0.004±0.004
Eosinophils %	0.044±0.270	0.950±0.270*** <sup>#</sup>	0.033±0.033
Mast cells × 10 <sup>4</sup> cells·mL <sup>-1</sup>	0.185±0.990	0.067±0.015*	0.030±0.013
Mast cells %	0.075±0.033	0.360±0.120**	0.200±0.089

Data are expressed as mean±SEM. AMs: alveolar macrophages; PMNs: polymorphonuclear neutrophils. \*: p<0.05, \*\*: p<0.01, \*\*\*: p<0.0001, all group I versus group II; #: p<0.05, ###: p<0.01, ####: p<0.0001 all versus control group.

The ALP activity was measured at 37°C by an enzymatic rate method using *p*-nitrophenylphosphate as a substrate. The test was performed on a Beckman Synchron CX-7 analyser (Beckman Instruments Inc) with Beckman reagents (testkit 442670). At an alkaline pH of 10.3, using a 2-amino-2-methyl-1 propanol (AMP) buffer, ALP catalyses the hydrolysis of the colourless organic phosphate ester substrate, *p*-nitrophenylphosphate, to the yellow coloured product *p*-nitrophenol and phosphate. The system monitors the rate of change in absorbance at 410 nm over a fixed-time interval. The rate of change in absorbance is directly proportional to the ALP activity, which is expressed in micromoles substrate (*p*-nitrophenylphosphate) converted per minute (U), per litre of serum, at 37°C. The measuring range is 10–800 U·L<sup>-1</sup>, for concentrations of 800–1800 U·L<sup>-1</sup> the samples were automatically diluted with saline and reanalysed, while manual dilution was performed for higher concentrations. Total protein and albumin were determined on a Synchron CX-7 analyser (Beckman Instruments Inc), using test kits (442740 and 442765, respectively) from Beckman Instruments Inc.

#### Statistical evaluation

Data are expressed as mean±SEM. In order to detect statistically significant differences between the two patients groups, for each explanatory variable separately, the Mann-Whitney U-test was used. Logistic regression was used to test the discriminatory effect of explanatory variables simultaneously. In these analyses, likelihood ratio tests were used; variables with a significance >10% were left out of the logistic regression models. The results are presented by means of receiver operation characteristics (ROC) curves [15].

## Results

The characteristics and serum laboratory results of the studied groups are summarized in table 1. The cellular profile, ALP, LDH and LDH isoenzyme activities in BALF samples of infectious and noninfectious aetiology were examined. The cellular characteristics of BALF of the studied groups are given in table 2. The enzyme and protein concentrations are summarized in table 3. The per-

Table 3. – Lactate dehydrogenase (LDH), percentage of LDH isoenzymes, alkaline phosphatase (ALP), total protein and albumin in bronchoalveolar lavage fluid (BALF) samples of group I (infectious aetiology), group II (noninfectious aetiology) patients and of healthy control subjects

	Group I (n=33)	Group II (n=47)	Control group (n=8)
Total protein mg·L <sup>-1</sup>	614±155 <sup>###</sup>	646±163 <sup>###</sup>	28±3
Albumin mg·L <sup>-1</sup>	297±97 <sup>###</sup>	344±96 <sup>###</sup>	17±2
ALP U·L <sup>-1</sup>	55±10 <sup>###</sup>	45±7 <sup>###</sup>	7±2
LDH U·L <sup>-1</sup>	662±125 <sup>###</sup>	147±22 <sup>*.#</sup>	64±4
LDH <sub>1</sub> %	3.0±0.3 <sup>###</sup>	8.6±0.9 <sup>*.###</sup>	14.5±2.1
LDH <sub>2</sub> %	6.9±0.5 <sup>###</sup>	15.6±0.8 <sup>*.###</sup>	23.1±1.5
LDH <sub>3</sub> %	13.7±0.6 <sup>###</sup>	25.2±0.7 <sup>*.###</sup>	29.1±0.8
LDH <sub>4</sub> %	22.1±0.5	26.4±0.6 <sup>*</sup>	22.9±1.7
LDH <sub>5</sub> %	54.3±1.5 <sup>###</sup>	24.0±1.6 <sup>*.###</sup>	10.5±0.9
LDH <sub>3</sub> /LDH <sub>5</sub>	0.27±0.02 <sup>###</sup>	1.57±0.20 <sup>*.###</sup>	2.86±0.24
LDH <sub>4</sub> /LDH <sub>5</sub>	0.44±0.02 <sup>###</sup>	1.43±0.12 <sup>*.#</sup>	2.21±0.15

Data are presented as mean±SEM. \*: p<0.0001 group I versus group II; #: p<0.05; ###: p<0.005 and ####: p<0.0001 all versus control group.

centage of AMs was significantly lower in the infectious group (7.0±1.3%) compared to the noninfectious group (47.4±3.7%; p<0.0001). The absolute number as well as the percentage of PMNs were significantly higher in the infectious group (309.6±81.3 × 10<sup>4</sup> cells·mL<sup>-1</sup> and 90.5±1.5%) compared to the noninfectious group (5.5±1.2 × 10<sup>4</sup> cells·mL<sup>-1</sup> and 21.6±3.4%; p<0.0001 and p<0.0001, respectively).

Between both patient populations with disorders of infectious and noninfectious aetiology, the ALP activity, albumin and total protein revealed no significant differences (table 3). However, compared to the control group, these parameters were significantly higher in both studied groups (table 3). The LDH activity in the BALF of group I (infectious aetiology) was significantly higher (662±125 U·L<sup>-1</sup>) compared to group II (147±22 U·L<sup>-1</sup>; p<0.0001). Moreover, the LDH isoenzyme pattern differed between both groups, particularly LDH<sub>5</sub> (table 3). The LDH<sub>3</sub>/LDH<sub>5</sub> and the LDH<sub>4</sub>/LDH<sub>5</sub> ratios were significantly lower in the BALF samples of infectious aetiology patients (0.27±0.02 and 0.44±0.02) compared to the




Fig. 1. – Scatterplot of polymorphonuclear neutrophils (PMNs) in bronchoalveolar lavage fluid (BALF) of patients with a bacterial pulmonary infection (Group I, n=33) and patients without a pulmonary infection (Group II, n=47).




Fig. 2. – Receiver-operating characteristic (ROC) curve of the absolute number of polymorphonuclear neutrophils (PMNs) per millilitre of fluid. Sensitivity is the probability of correctly predicting the infectious group. Specificity is the probability of correctly predicting the noninfectious group. Area under the ROC curve is 0.9774. The diagonal line represents the points where sensitivity equals specificity=50%.

noninfectious BALF samples (1.57±0.20 and 1.43±0.12; p<0.0001). In serum, LDH was elevated in the infectious group (727±50 U·L<sup>-1</sup>) as well as in the noninfectious group (1026±262 U·L<sup>-1</sup>) compared to the control group (p<0.001), but no significant difference was found between both groups, respectively (table 1).

When using only the absolute number of PMNs per millilitre of fluid, the sensitivity of predicting the correct group was 100 (45/47)=95.7%, with a lower specificity of 100 (28/33)=84.8% (cutoff point 23.7 × 10<sup>4</sup> mL<sup>-1</sup>) (figs. 1 and 2). As shown in figure 3, with respect to the enzyme activity, logistic regression analysis revealed the best discrimination between both groups using the LDH<sub>4</sub>/LDH<sub>5</sub> ratio with a sensitivity of 100 (44/47)=93.6% and a specificity of 100 (31/33)=93.9% (cutoff point 0.60). A LDH<sub>4</sub>/LDH<sub>5</sub> ratio >0.80 pointed to a noninfectious nature of the BALF with a 100% specificity, at the cost, however, of a lower sensitivity of 100 (33/47)=70.2%. In contrast, a LDH<sub>4</sub>/LDH<sub>5</sub> ratio <0.50 was indicative for an




Fig. 3. – Receiver-operating characteristic curve (ROC) of the lactate dehydrogenase (LDH)<sub>4</sub>/LDH<sub>5</sub> ratio. Sensitivity is the probability of correctly predicting the infectious group. Specificity is the probability of correctly predicting the noninfectious group. Area under the ROC curve is 0.9847. The diagonal line represents the points where sensitivity equals specificity=50%.

infectious nature of the BALF with a specificity of 100% and a sensitivity of 100 (28/33)=84.8%, respectively. Using the LDH<sub>3</sub>/LDH<sub>5</sub> ratio, a sensitivity of 100 (45/47)=95.7% and a specificity of 100 (29/33)=87.9% was found. The smoking history was of no influence on the results.

The majority of cases from group I (n=25, 76%) were intubated and mechanically ventilated patients from the ICU. In group II, 55% (n=26) of the cases were patients from the hospital ward and the other 45% (n=25) were intubated and mechanically ventilated patients from the ICU. Statistical analyses were performed between these subgroups. Although these results (data not shown) demonstrate that there is a difference between intubated and non-intubated cases in both groups, the nonintubated cases of group I still had a significantly higher number of PMNs as well as a lower LDH<sub>4</sub>/LDH<sub>5</sub> ratio in BALF compared to the intubated patients from group II.

In the group of noninfectious BALF samples, four patients were diagnosed as having ARDS. In this latter subgroup, the absolute number ( $5.56 \pm 3.66 \times 10^4$  cells·mL<sup>-1</sup>) and relative number of PMNs (30±13%), the LDH ( $168 \pm 54$  U·L<sup>-1</sup>) and LDH<sub>4</sub>/LDH<sub>5</sub> ratio ( $1.15 \pm 0.34$ ) in BALF, were also significantly different from the BALF samples of the infectious aetiology group.

### Discussion

This study demonstrated that the cellular profile of BALF samples of infectious aetiology appeared to be significantly different from samples of noninfectious aetiology. In particular, the absolute and relative number of PMNs were significantly higher in the infectious group. Furthermore, the LDH activity in BALF was higher in the infectious group compared to the noninfectious group. More specifically, the LDH isoenzyme pattern differed between both groups, of which LDH<sub>5</sub> was the most prominent. The best discriminator between both groups appeared to be the LDH<sub>4</sub>/LDH<sub>5</sub> ratio. The ALP activity, albumin and total protein concentrations in BALF revealed no significant differences between both groups.

#### *Cellular bronchoalveolar lavage fluid profile*

In addition to their defensive role, PMNs and AMs have recently been implicated in injurious processes associated with both acute and chronic pulmonary diseases [16]. In the normal lung, AMs are resident cells, whereas PMNs are usually absent. However, in certain conditions, PMNs can accumulate within the lung structures [1, 16]. Until now, little attention has been paid to the usefulness of this particular cell type in distinguishing BALF samples of infectious aetiology from noninfectious aetiology. Previously, KIRTLAND *et al.* [17] found that <50% PMNs in BALF had a 100% negative predictive value for histologic pneumonia. MARQUETTE *et al.* [18] also found increased PMNs in patients with pneumonia (87±13%) in comparison to patients without pneumonia (49±32%). In agreement with these findings, the present study found a high total cell count as well as increased numbers of PMNs in the BALF samples of the infectious aetiology group compared to the group of noninfectious aetiology. Moreover, analysis of the cellular profile appeared to be useful in identifying other causes of the pulmonary damage such as fibrosis, drug-induced pneumonitis, diffuse alveolar dam-

age [19, 20] and malignant infiltrates [5, 21]. Furthermore, extracellular bacteria, neutrophils with intracellular bacteria [6] and elastin fibres [22] were more frequently observed in Gram-stained samples of cytocentrifuged BALF obtained from patients with pneumonia compared to patients without pneumonia [4].

#### *Lactate dehydrogenase activity in bronchoalveolar lavage fluid*

The enzyme activity in BALF may provide a quantitative assessment of cell damage and pulmonary defence mechanisms. As mentioned previously, not only the amount of cells involved in an inflammatory response are of importance, but also the activity reflected by the release of inflammatory mediators or enzymes indicating cell damage or death such as LDH and ALP [23]. Many studies in animals reported the relationship between LDH activity and pulmonary disorders [23, 24]. In humans, high serum LDH activity was found in several pathological pulmonary conditions, such as pulmonary embolism, *P. carinii* pneumonia, tuberculosis, bacterial pneumonia [25], diffuse interstitial pneumonitis, extrinsic allergic alveolitis [26], drug-induced respiratory distress [20], lipoid pneumonia [19], idiopathic pulmonary fibrosis [26, 27] and silicosis [28]. Furthermore, LDH activity in sputum appeared to be useful to differentiate lower respiratory tract infections from other clinical entities [29]. The LDH and ALP activity has been found to be higher in BALF with mainly PMNs compared to BALF with predominantly AMs [11]. This finding was consistent with the higher inflammatory response indicated by the PMNs [30]. In line with this, in the present study, the number of PMNs as well as the LDH activity was higher in the BALF samples of infectious aetiology. Furthermore, in a previous study [11], the LDH isoenzyme pattern in BALF samples with predominantly PMNs differed from BALF samples with mainly AMs, mainly due to a high LDH<sub>5</sub> level, and as a consequence a lower LDH<sub>3</sub>/LDH<sub>5</sub> ratio. In the present study, a different LDH isoenzyme pattern in the group of BALF samples of infectious aetiology compared to the samples of noninfectious aetiology was found. Comparable with the higher amount of PMNs in the infectious group, a different LDH isoenzyme pattern was also found, with a lower LDH<sub>3</sub>/LDH<sub>5</sub> and LDH<sub>4</sub>/LDH<sub>5</sub> ratio, mainly due to the higher LDH<sub>5</sub> activity observed. In addition to the absolute amount of PMNs, the LDH<sub>4</sub>/LDH<sub>5</sub> ratio appeared to be a good discriminator between the infectious and noninfectious group.

Distinguishing ARDS from active pulmonary infections at an early stage is of great clinical importance as both entities require a different therapeutic approach [31]. MEDURI *et al.* [32] and STEINBERG *et al.* [33] reported a marked neutrophilia in BALF in ARDS, predominantly in early ARDS. These studies included patients with sepsis-induced ARDS. The noninfectious group of the present study included only four patients suffering from ARDS. Compared to the infectious group, these four cases had a lower number of PMNs, lower LDH<sub>5</sub> activity and a higher LDH<sub>4</sub>/LDH<sub>5</sub> ratio. These results should be interpreted with care due to the rather limited sample size of the studied ARDS population and the different time between the onset of ARDS and lavage. The results of

BALF depend on the phase of ARDS (exudative, proliferative and fibrotic) [34]. Furthermore, different mechanisms may be present in ARDS that develop after trauma, infectious aetiology such as sepsis, or other conditions. Future studies are required to evaluate the clinical relevance of including cellular and biochemical analysis to distinguish patients with ARDS from patients with pneumonia.

#### *Alkaline phosphatase in bronchoalveolar lavage fluid*

Type II pneumocytes are important in the repair of alveolar epithelium after injury and response to oxidant stress (such as hypoxaemia). Normally, type II cells are not present in BALF [9, 35]. The ALP activity, a marker of type II cell damage and/or proliferation was reported to be increased in BALF after exposure to pneumotoxicants [9, 24, 36] and associated with progression of fibrosis [35]. In both patient populations of the present study, the BALF samples showed high ALP activity compared to the control group, indicating type II involvement in the pathophysiological process. However, no difference in ALP activity was found between BALF samples of infectious and noninfectious aetiology, respectively. As a result, ALP activity, in contrast to LDH, did not differentiate between inflammatory processes of infectious or noninfectious aetiology.

#### *Advantage of additional enzyme detection in bronchoalveolar lavage fluid*

The sensitivity of detecting an increase of the enzyme activity in BALF was found to be minimally dependent on the volume of fluid used for lavage (data not shown) in contrast to cell counting [37]. Furthermore, assessing enzymatic markers of inflammation and cell damage, such as ALP, LDH and LDH isoenzyme activities, appeared to be of additional value to identify which inflammatory cells were involved in the pathologic process. Therefore, if it is not possible to assess the total and differential cell count, monitoring biochemical changes may be of value to establish the inflammatory cell status of a patient. Moreover, due to interobservant differences, cell counting can vary [38], whilst the measurement of enzymes is well standardized and reproducible. Measurement of LDH, ALP activity and LDH isoenzymes can be achieved within a 2-h period. Thus, enzyme activities can be available without delay. More important, these relatively cheap and easy to perform measurements are applicable in every hospital.

#### *Conclusion*

In conclusion, assessment of the total and differential cell count as well as monitoring biochemical changes in bronchoalveolar lavage fluid appeared to be of additional value in the diagnostic work-up of patients with suspected pneumonia. In particular, the absolute number of polymorphonuclear neutrophils, but even more the lactate dehydrogenase 4/lactate dehydrogenase 5 ratio in bronchoalveolar lavage fluid demonstrated a positive predictive value in distinguishing disorders of infectious and non-infectious aetiology. Further studies are required to support the potential clinical relevance of adding cell counting and

biochemical analysis to the microbiological analysis of bronchoalveolar lavage fluid in general.

#### **References**

1. Costabel U. Bronchoalveolar lavage characteristics of the bronchiolar diseases. *In: Epler GR, ed. Diseases of the bronchioles.* New York, Raven Press, Ltd. 1994; 59–76.
2. Cobben NAM, Drent M, Jonkers M, Wouters EFM, Vaneechoutte M, Stobberingh EE. Outbreak of severe *Pseudomonas aeruginosa* respiratory infections due to contaminated nebulizers. *J Hosp Infect* 1996; 33: 63–70.
3. Gerbeaux P, Ledoray V, Boussuges A, Molenat F, Jean P, Sainty M. Diagnosis of nosocomial pneumonia in mechanically ventilated patients. *Am J Respir Crit Care Med* 1998; 157: 76–80.
4. Bonten MJM, Gaillard CA, Wouters EFM, Tiel van FH, Stobberingh EE, Geest van der S. Problems in diagnosing nosocomial pneumonia in mechanically ventilated patients: a review. *Am J Respir Crit Care Med* 1994; 22: 1683–1691.
5. Klech H, Hutter C, Costabel U. Clinical guidelines and indications for bronchoalveolar lavage: report of the European Society of Pneumology Task Group on BAL. *Eur Respir J* 1992; 2: 47–127.
6. Torres A, El-Ebiary M, Gonzalez J, *et al.* Value of intracellular bacteria detection in the diagnosis of ventilator associated pneumonia. *Thorax* 1996; 51: 378–384.
7. Bonten MJM, Froon AHM, Gaillard CA, *et al.* The systemic inflammatory response in the development of ventilator associated pneumonia. *Am J Respir Crit Care Med* 1997; 156: 1105–1113.
8. Henderson RF. Analysis of respiratory tract lining fluids to detect injury. *In: Hollinger MA, ed. Focus on pulmonary pharmacology and toxicology.* CRC Press Inc. 1991; 1–18.
9. Henderson RF, Scott GG, Waide JJ. Source of alkaline phosphatase activity in epithelial lining fluid of normal and injured F344 rat lungs. *Toxicol Appl Pharmacol* 1995; 134: 170–174.
10. Drent M, Cobben NAM, Henderson RF, Jacobs JA, Wouters EFM, Dieijen-Visser van MP. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage and inflammation. *Eur Respir J* 1996; 9: 1736–1742.
11. Cobben NAM, Drent M, Jacobs JA, *et al.* Relationship between enzymatic markers of pulmonary cell damage and cellular profile: a study in bronchoalveolar lavage fluid. *Exp Lung Res* 1999; 25: 99–111.
12. Drent M, Van Nierop MAMF, Gerritsen FA, Wouters EFM, Mulder PGH. Computer program using BALF analysis results as diagnostic tool in interstitial lung diseases. *Am J Respir Crit Care Med* 1996; 153: 736–741.
13. Brauwer de E, Jacobs JA, Nieman F, Bruggeman C, Drent M. Test characteristics of acridine orange, Gram and May-Grünwald-Giemsa Stains for enumeration of intracellular organisms in bronchoalveolar lavage fluid. *J Clin Microbiol* 1999; 37: 427–429.
14. Beckman Instruments Inc. Lactate dehydrogenase and isoenzymes. Germany: Synchron CX Systems Chemistry Information, 1993.
15. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. *Clin Chem* 1993; 39: 561–577.
16. Sibille S, Reynolds HY. State of the art: Macrophages and polymorphonuclear neutrophils in lung defence and injury. *Am Rev Respir Dis* 1990; 141: 471–501.

17. Kirtland SH, Corley DE, Winterbauer RH, *et al.* The diagnosis of ventilator associated pneumonia. *Chest* 1997; 112: 445–457.
18. Marquette CH, Copin MC, Wallet F, *et al.* Diagnostic test for pneumonia in ventilated patients: prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. *Am J Respir Crit Care Med* 1995; 151: 1878–1888.
19. Drent M, Cobben NAM, Henderson RF, Wouters EFM, Dieijen-Visser van MP. BAL fluid LDH activity and LDH isoenzyme pattern in lipid pneumonia caused by an intravenous injection of lamp-oil. *Eur Respir J* 1996; 9: 2416–2418.
20. Wilschut FA, Cobben NAM, Thunnissen FBJM, Lamers RJS, Wouters EFM, Drent M. Recurrent respiratory distress associated with carbamazepine overdose. *Eur Respir J* 1997; 10: 2163–2165.
21. Drent M, Peters FPJ, Jacobs JA, Maassen van de Brink KI, Wagenaar SJS, Wouters EFM. Pulmonary infiltration associated with myelodysplasia. *Ann Oncol* 1997; 8: 905–909.
22. Salata RA, Lederman MM, Schlacs DM. Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. *Am Rev Respir Dis* 1987; 135: 426–432.
23. Henderson RF. Use of bronchoalveolar lavage to detect lung damage. *Environ Health Perspect* 1984; 56: 115–129.
24. Janssen YMW, Marsh JP, Absher MP, *et al.* Expression of antioxidant enzymes in rat lungs after inhalation of asbestos or silica. *J Biol Chem* 1992; 267: 10625–10630.
25. Quist J, Hill AR. Serum lactate dehydrogenase (LDH) on *Pneumocystis carinii*, tuberculosis and bacterial pneumonia. *Chest* 1995; 108: 415–418.
26. Matusiewicz SP, Williamson IJ, Sime PJ, *et al.* Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis? *Eur Respir J* 1993; 6: 1282–1286.
27. Krugten van M, Cobben NAM, Lamers RJS, *et al.* Serum LDH: a marker of disease activity and its response to therapy in idiopathic pulmonary fibrosis. *Neth J Med* 1996; 48: 220–223.
28. Cobben NAM, Drent M, Schols AMWJ, Lamers RJS, Wouters EFM, Dieijen-Visser van MP. Serum lactate dehydrogenase and its isoenzyme pattern in ex-coalminers. *Respir Med* 1997; 91: 616–623.
29. Efferey LS, Ng R, Palat D. Utility of sputum lactate dehydrogenase levels in diagnosing acute infectious bronchopulmonary disease. *Am J Respir Crit Care Med* 1994; 149: A340.
30. Henderson RF, Harkema JR, Hotchkiss JA, Boehme DS. Effect of blood leucocyte depletion on the inflammatory response of the lung to quartz. *Toxicol Appl Pharmacol* 1991; 109: 127–136.
31. Chastre J, Trouillet JL, Vuagnat A, *et al.* Nosocomial pneumonia in patients with acute respiratory distress syndrome. *Am J Crit Care Med* 1998; 157: 1165–1172.
32. Meduri GU. The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. *Eur Respir J* 1996; 9: 2650–2670.
33. Steinberg KP, Milberg JA, Martin TR, Maunders RJ, Cockrill BA, Hudson LD. Evolution of bronchoalveolar cell populations in the acute respiratory distress syndrome. *Am J Respir Crit Care Med* 1994; 150: 113–122.
34. Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane. *Thorax* 1998; 53: 815–817.
35. Capelli A, Lusuardi M, Cerutti CG, Donner CF. Lung alkaline phosphatase as a marker of fibrosis in chronic interstitial disorders. *Am J Respir Crit Care Med* 1997; 155: 249–253.
36. Edelson JD, Shannon JM, Mason RJ. Alkaline phosphatase: a marker of alveolar type II cell differentiation. *Am Rev Respir Dis* 1988; 138: 1268–1275.
37. Drent M, Mulder PGH, Wagenaar SJS, *et al.* Differences in BAL fluid variables in interstitial lung diseases evaluated by discriminant analysis. *Eur Respir J* 1993; 6: 803–810.
38. Kleyklamp BO, Baughman RP. Who should perform bronchoalveolar lavage analysis? *Am J Respir Crit Care Med* 1998; 157: A67.